

Angelo Armandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5863034/publications.pdf>

Version: 2024-02-01

50
papers

742
citations

687363

13
h-index

580821

25
g-index

51
all docs

51
docs citations

51
times ranked

721
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
2	Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.5	2
3	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	2.2	4
4	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	2.4	12
5	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. <i>Biomedicines</i> , 2022, 10, 792.	3.2	4
6	The use of Spleen Stiffness Measurement for the detection of high-risk esophageal varices in patients with portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, S19-S20.	0.9	0
7	Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives. <i>Animals</i> , 2022, 12, 812.	2.3	4
8	Autoimmunity of the liver. , 2022, , 309-331.		0
9	NAFLD between genes and environment: what drives fibrogenesis?. <i>Gut</i> , 2021, 70, 815-816.	12.1	5
10	Do not forget celiac disease in women with iron deficiency anemia. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2021, 179, .	0.1	0
11	Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis. <i>Minerva Biotecnologica</i> , 2021, 32, .	1.2	3
12	Seronegative occult hepatitis C virus infection: what is its clinical relevance?. <i>Minerva Biotecnologica</i> , 2021, 32, .	1.2	0
13	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	2.8	4
14	Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum. <i>Minerva Biotechnology and Biomolecular Research</i> , 2021, 33, .	0.5	0
15	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 155.	2.9	44
16	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101611.	1.5	0
17	Increased serum ferritin levels predict long-term mortality in patients with NAFLD. <i>Digestive and Liver Disease</i> , 2021, 53, S28.	0.9	1
18	Inflammatory Bowel Disease Nurseâ€™ Practical Messages. <i>Nursing Reports</i> , 2021, 11, 229-241.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Tight junction regulation in celiac disease: role of larazotide acetate. <i>Minerva Gastroenterology</i> , 2021, , .	0.5	1
20	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	9
21	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	3.7	24
22	Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. <i>Minerva Gastroenterology</i> , 2021, , .	0.5	0
23	Natural history of NASH. <i>Liver International</i> , 2021, 41, 78-82.	3.9	16
24	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. <i>Nutrients</i> , 2021, 13, 1977.	4.1	17
25	A Retrospective Experience of <i>Helicobacter pylori</i> Histology in a Large Sample of Subjects in Northern Italy. <i>Life</i> , 2021, 11, 650.	2.4	1
26	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohnâ€™s Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	2.4	16
27	Outcomes and potential surrogate markers for future clinical trials of nonâ€™alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021, 41, 1999-2008.	3.9	7
28	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3257.	2.4	2
29	Impact of thyroid disorders on the incidence of nonâ€™alcoholic fatty liver disease in Germany. <i>United European Gastroenterology Journal</i> , 2021, 9, 829-836.	3.8	9
30	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
31	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
32	Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 187.	2.6	9
33	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium lactis</i> , and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4961.	2.4	8
34	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 716533.	3.5	27
35	Can Periodontitis Affect the Health and Disease of the Digestive System? A Comprehensive Review of Epidemiological Evidence and Biological Mechanisms. <i>Current Oral Health Reports</i> , 2021, 8, 96-106.	1.6	5
36	NAFLD and NASH: The Metabolically Diseased Liver. <i>Handbook of Experimental Pharmacology</i> , 2021, , 253-267.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Editorial: the polygenic risk of cirrhosis development. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 849-850.	3.7	0
38	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021, 67, 196-208.	0.5	3
39	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	4.1	22
40	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with <i>Bifidobacterium Longum</i> ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	2.4	18
41	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.4	9
42	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
43	Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic subjects with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S165.	3.7	1
44	Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S405.	3.7	0
45	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	3.7	27
46	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 800.	2.4	29
47	Moving towards core antigen for the management of patients with overt and occult HBV infection. <i>Panminerva Medica</i> , 2020, , .	0.8	4
48	Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. <i>Minerva Biotechnologica</i> , 2019, 31, .	1.2	7
49	Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1138-1145.	3.7	10
50	Steroidomic approach for the characterization of patients with non-alcoholic fatty liver disease. <i>Endocrine Abstracts</i> , 0, , .	0.0	0